Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Synergic anticancer effects of morin hydrate and sorafenib delivered via polymeric iron oxide nanoparticles for the treatment of triple-negative breast cancer.

Created on 15 Aug 2026

Authors

Mingjun Li, Chaohui Wang, Zhenhua Sun

Published in

Naunyn-Schmiedeberg's archives of pharmacology. Aug 14, 2026. Epub Aug 14, 2026.

Abstract

A magnetic codelivery method using morin hydrate (MH) and sorafenib (SF) was used to control cancer recurrence in human triple-negative breast cancer (TNBC). Combined with anticancer drugs, SF and MH showed synergistic effects in TNBC treatment. Nevertheless, their dissimilar polarities make co-encapsulation using traditional delivery methods challenging. Hence, in this study, MH-, SF-loaded zein (ZN)-, and chitosan (CS)-coated iron oxide (Fe3O4) (termed MH-SF/ZN@CS/Fe3O4) were developed via layer-by-layer deposition and anti-solvent precipitation to overcome these problems and increase therapeutic efficacy. Nanoparticles with an average diameter of 20 nm were fabricated. Approximately 18% and 16% of SF and MH drug-loading contents were present, respectively. An intriguing degree of pH sensitivity was observed, with SF and MH release from MH-SF/ZN@CS/Fe3O4 faster at pH 6.5 than at pH 7.4. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay demonstrated that MH/SF-loaded magnetic polymeric nanoparticles displayed considerable synergistic in vitro cytotoxicity against MDA-MB-231 TNBC cells compared to other groups. Cell morphology and apoptosis mechanism were investigated, showing that MH-SF/ZN@CS/Fe3O4 induced apoptosis in MDA-MB-231 cancer cells. Morphological investigation of cancer cells was conducted via biochemical analysis, and the apoptotic mechanism of the cells was examined using flow cytometry with Annexin V-fluorescein isothiocyanate and propidium iodide. These findings indicate the potential of dual-drug-loaded magnetic polymeric nanoparticles for targeting cancer cells.

PMID:
42599405
Bibliographic data and abstract were imported from PubMed on 15 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement